Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Better Therapeutics, Inc. stock logo
BTTX
Better Therapeutics
$0.00
$0.00
$0.00
$0.00
$4K0.896,546 shs113 shs
Hudson Executive Investment Corp. stock logo
HEC
Hudson Executive Investment
$5.16
$8.58
$7.82
$12.45
$213.62MN/A1.42 million shs2.17 million shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.13
+1.8%
$1.18
$0.98
$1.60
$838.15M1.422.36 million shs1.76 million shs
UPHL
UpHealth
$0.00
$0.00
$0.05
$2K0.862,544 shs81 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Better Therapeutics, Inc. stock logo
BTTX
Better Therapeutics
0.00%0.00%0.00%0.00%-50.00%
Hudson Executive Investment Corp. stock logo
HEC
Hudson Executive Investment
0.00%0.00%-0.39%+25.24%+61.76%
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.00%-8.33%-3.51%-12.70%-20.58%
UPHL
UpHealth
0.00%0.00%-50.00%-50.00%-50.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Better Therapeutics, Inc. stock logo
BTTX
Better Therapeutics
$0.00
$0.00
$0.00
$0.00
$4K0.896,546 shs113 shs
Hudson Executive Investment Corp. stock logo
HEC
Hudson Executive Investment
$5.16
$8.58
$7.82
$12.45
$213.62MN/A1.42 million shs2.17 million shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.13
+1.8%
$1.18
$0.98
$1.60
$838.15M1.422.36 million shs1.76 million shs
UPHL
UpHealth
$0.00
$0.00
$0.05
$2K0.862,544 shs81 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Better Therapeutics, Inc. stock logo
BTTX
Better Therapeutics
0.00%0.00%0.00%0.00%-50.00%
Hudson Executive Investment Corp. stock logo
HEC
Hudson Executive Investment
0.00%0.00%-0.39%+25.24%+61.76%
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.00%-8.33%-3.51%-12.70%-20.58%
UPHL
UpHealth
0.00%0.00%-50.00%-50.00%-50.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Better Therapeutics, Inc. stock logo
BTTX
Better Therapeutics
0.00
N/AN/AN/A
Hudson Executive Investment Corp. stock logo
HEC
Hudson Executive Investment
0.00
N/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
2.17
Hold$1.5537.17% Upside
UPHL
UpHealth
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest HEC, BTTX, UPHL, and OPK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/29/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
DowngradeOutperformMarket Perform
4/21/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
Reiterated RatingSell (D-)
3/2/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
Lower Price TargetOutperform$2.25 ➝ $1.50
(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Better Therapeutics, Inc. stock logo
BTTX
Better Therapeutics
N/AN/AN/AN/AN/AN/A
Hudson Executive Investment Corp. stock logo
HEC
Hudson Executive Investment
N/AN/AN/AN/A$0.12 per shareN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
$606.90M1.41N/AN/A$1.60 per share0.71
UPHL
UpHealth
$130M0.00N/AN/A$3.10 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Better Therapeutics, Inc. stock logo
BTTX
Better Therapeutics
-$39.76M-$0.78N/AN/AN/AN/AN/AN/A5/14/2026 (Estimated)
Hudson Executive Investment Corp. stock logo
HEC
Hudson Executive Investment
-$27.24MN/AN/AN/AN/AN/A-337.48%-4.06%N/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$225.68M-$0.27N/AN/AN/A-36.63%-16.78%-10.98%N/A
UPHL
UpHealth
-$56.42M$1.47N/AN/AN/AN/AN/AN/AN/A

Latest HEC, BTTX, UPHL, and OPK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2026N/A
Better Therapeutics, Inc. stock logo
BTTX
Better Therapeutics
-$0.22N/AN/AN/A$5.04 millionN/A
4/28/2026Q1 2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07-$0.07N/A-$0.07$130.51 million$124.20 million
2/26/2026Q4 2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07-$0.04+$0.03-$0.04$139.76 million$148.50 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Better Therapeutics, Inc. stock logo
BTTX
Better Therapeutics
N/AN/AN/AN/AN/A
Hudson Executive Investment Corp. stock logo
HEC
Hudson Executive Investment
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
UPHL
UpHealth
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Better Therapeutics, Inc. stock logo
BTTX
Better Therapeutics
N/AN/AN/A
Hudson Executive Investment Corp. stock logo
HEC
Hudson Executive Investment
N/A
0.33
0.33
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.28
3.61
3.17
UPHL
UpHealth
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Better Therapeutics, Inc. stock logo
BTTX
Better Therapeutics
34.00%
Hudson Executive Investment Corp. stock logo
HEC
Hudson Executive Investment
73.41%
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%
UPHL
UpHealth
56.10%

Insider Ownership

CompanyInsider Ownership
Better Therapeutics, Inc. stock logo
BTTX
Better Therapeutics
51.40%
Hudson Executive Investment Corp. stock logo
HEC
Hudson Executive Investment
N/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
49.69%
UPHL
UpHealth
34.24%
CompanyEmployeesShares OutstandingFree FloatOptionable
Better Therapeutics, Inc. stock logo
BTTX
Better Therapeutics
4040.58 million24.23 millionNo Data
Hudson Executive Investment Corp. stock logo
HEC
Hudson Executive Investment
N/A41.40 millionN/ANot Optionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
1,373755.09 million379.89 millionOptionable
UPHL
UpHealth
1,75018.93 million12.45 millionNo Data

Recent News About These Companies

UpHealth Delays Q2 2025 10-Q Filing
Lemon Dump Cake Recipe
DJUSIV Dow Jones US Business Support Services Index
UpHealth Inc Ordinary Shares UPHL
UpHealth, Inc. (UPHL)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Better Therapeutics stock logo

Better Therapeutics NASDAQ:BTTX

$0.0001 0.00 (0.00%)
As of 09:30 AM Eastern

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.

Hudson Executive Investment stock logo

Hudson Executive Investment NASDAQ:HEC

Hudson Executive Investment Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.13 +0.02 (+1.80%)
Closing price 04:00 PM Eastern
Extended Trading
$1.13 0.00 (0.00%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

UpHealth NYSE:UPHL

UpHealth, Inc. provides behavioral health solutions through the utilization of evidence-based treatments and services in the Americas. The company offers mental health and substance use disorder treatment services directly to consumers. It also provides detoxification, residential, partial hospitalization program, intensive outpatient program, outpatient services, and non-clinical recovery residence and supporting housing services. UpHealth, Inc. is headquartered in Delray Beach, Florida.